In 2019, another group employed ddPCR for detecting MYD88L265P mutation in a cohort of 39 patients; with a sensitivity of 1 × 10−3, the authors identified the mutation in 90% of MW cases, in 44% of patients affected by LPL, in 5% of IgM MM, and no in CLL or mantle cell lymphoma (MCL) cases [90]. This evidence concerns the gene LPL and mantle cell lymphoma.